{
    "organizations": [],
    "uuid": "9e6aea82f9f6fb42786a1957c5b7180a910659a3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-g1-therapeutics-announces-initiati/brief-g1-therapeutics-announces-initiation-of-phase-1b-2-clinical-trial-of-g1t38-in-combination-with-tagrisso-idUSASC09VVP",
    "ord_in_thread": 0,
    "title": "BRIEF-G1 Therapeutics Announces Initiation Of Phase 1B/2 Clinical Trial Of G1T38 In Combination With Tagrisso",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16, 2018 / 10:03 AM / Updated 12 minutes ago BRIEF-G1 Therapeutics Announces Initiation Of Phase 1B/2 Clinical Trial Of G1T38 In Combination With Tagrisso Reuters Staff 1 Min Read \nApril 16 (Reuters) - G1 Therapeutics Inc: \n* G1 THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1B/2 CLINICAL TRIAL OF G1T38 IN COMBINATION WITH TAGRISSO FOR EGFR-MUTANT NON-SMALL CELL LUNG CANCER \n* G1 THERAPEUTICS INC - ASTRAZENECA IS PROVIDING TAGRISSO FOR PHASE 1B/2 CLINICAL TRIAL UNDER NON-EXCLUSIVE CLINICAL TRIAL COLLABORATION AGREEMENT \n* G1 THERAPEUTICS - OPEN-LABEL TRIAL IS EXPECTED TO ENROLL APPROXIMATELY 145 PARTICIPANTS IN TWO PARTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-16T13:02:00.000+03:00",
    "crawled": "2018-04-16T13:24:58.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "announces",
        "initiation",
        "phase",
        "clinical",
        "trial",
        "g1t38",
        "combination",
        "tagrisso",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "g1",
        "therapeutic",
        "inc",
        "g1",
        "therapeutic",
        "announces",
        "initiation",
        "phase",
        "clinical",
        "trial",
        "g1t38",
        "combination",
        "tagrisso",
        "cell",
        "lung",
        "cancer",
        "g1",
        "therapeutic",
        "inc",
        "astrazeneca",
        "providing",
        "tagrisso",
        "phase",
        "clinical",
        "trial",
        "clinical",
        "trial",
        "collaboration",
        "agreement",
        "g1",
        "therapeutic",
        "trial",
        "expected",
        "enroll",
        "approximately",
        "participant",
        "two",
        "part",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}